Oncology Update

The U.S. Food and Drug Administration (FDA) has approved oral vismodegib (Erivedge™) for the treatment of adult patients with locally advanced basal cell carcinoma who are not candidates for surgery or radiation and for those with metastatic disease. The drug initially was tested at Scottsdale Healthcare in Arizona.